Back to Snakebite Envenoming
ACCEPTEDv1Snakebite Envenoming

The Biggest Neglected Tropical Disease You've Never Funded: Snakebite Envenoming

Snakebite envenoming kills and disables hundreds of thousands of the world's poorest rural people each year, yet has long been ignored by pharma and donors alike. This founding report documents the burden, explains the antivenom supply-chain and delivery failures at the heart of the problem, and lays out the WHO roadmap and funding gaps that make this a high-impact neglected niche.

WorldProblems Solved AdminJun 4, 2026
397 words2 min read

The Biggest Neglected Tropical Disease You've Never Funded: Snakebite Envenoming

Executive Summary

Snakebite envenoming is one of the most neglected public health crises in the world. It kills an estimated 81,000–138,000 people every year and leaves roughly three times as many with permanent disabilities — amputations, blindness, kidney failure, and disfigurement. Its victims are overwhelmingly poor rural agricultural workers and children in sub-Saharan Africa and South Asia, with little political voice. Effective treatments exist but rarely reach those who need them.

The Scale of the Problem

The WHO estimates roughly 5.4 million snakebites a year, of which 1.8–2.7 million result in envenoming, causing 81,410–137,880 deaths and an estimated 250,000–400,000 permanent disabilities or amputations annually. The burden is concentrated among the rural poor, far from health facilities, and is widely under-reported.

Why It Persists (The Delivery Problem)

Unlike many neglected diseases, the core issue is not the absence of a treatment but the failure to deliver it:

  • Antivenom is region-specific: Products must match the venoms of local snake species; antivenoms developed for one region can be useless or dangerous elsewhere.
  • Cold-chain logistics: Many antivenoms require refrigeration unavailable in remote clinics.
  • Cost and access: Treatment can be unaffordable for subsistence families and unavailable at the nearest facility.
  • Weak rural health systems: Delays in reaching care turn survivable bites into fatal or disabling ones.
  • Market failure: Low ability to pay has driven manufacturers out, causing antivenom shortages.

The Neglectedness Landscape

Snakebite was long ignored entirely; the Wellcome Trust's roughly £80 million commitment (2019) is essentially the only large dedicated funding effort, tiny relative to the death and disability burden. The WHO has set a roadmap to halve snakebite deaths and disability by 2030, but it remains badly under-resourced.

Tractable Directions

  1. Strengthen antivenom supply chains — production, quality assurance, and regional matching.
  2. Improve rural delivery — stockpiling, cold-chain, and training at first-contact facilities.
  3. Community awareness of first aid and the importance of rapid care-seeking.
  4. Next-generation treatments — heat-stable, broad-spectrum antivenoms and small-molecule inhibitors.

Recommendations

  1. Fund the WHO 2030 roadmap and antivenom supply-chain strengthening.
  2. Invest in heat-stable, broad-spectrum treatments to overcome cold-chain barriers.
  3. Support rural delivery and community education in high-burden regions.

Further Reading

  • WHO, Snakebite Envenoming Fact Sheet (2024) and 2030 roadmap
  • Wellcome Trust snakebite program
  • Gutiérrez et al., "Snakebite envenoming," Nature Reviews Disease Primers (2017)